-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Financial Analysis: CorMedix (NYSE:CRMD) Vs. ORIC Pharmaceuticals (NASDAQ:ORIC)
Financial Analysis: CorMedix (NYSE:CRMD) Vs. ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) and CorMedix (NYSE:CRMD – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
89.7% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 33.8% of CorMedix shares are held by institutional investors. 6.2% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Get ORIC Pharmaceuticals alerts:Profitability
This table compares ORIC Pharmaceuticals and CorMedix's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ORIC Pharmaceuticals | N/A | -32.11% | -29.50% |
CorMedix | -25,202.44% | -48.87% | -44.76% |
Volatility and Risk
ORIC Pharmaceuticals has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.Analyst Ratings
This is a breakdown of current ratings for ORIC Pharmaceuticals and CorMedix, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ORIC Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
CorMedix | 0 | 0 | 0 | 0 | N/A |
ORIC Pharmaceuticals currently has a consensus price target of $22.00, suggesting a potential upside of 379.30%. Given ORIC Pharmaceuticals' higher probable upside, equities analysts clearly believe ORIC Pharmaceuticals is more favorable than CorMedix.
Earnings and Valuation
This table compares ORIC Pharmaceuticals and CorMedix's gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ORIC Pharmaceuticals | N/A | N/A | -$78.71 million | ($2.15) | -2.13 |
CorMedix | $190,000.00 | 926.08 | -$28.21 million | ($0.79) | -5.42 |
CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.
About ORIC Pharmaceuticals
(Get Rating)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
About CorMedix
(Get Rating)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) and CorMedix (NYSE:CRMD – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
奥利克制药(纳斯达克:ORIC-GET评级)和CorMedex(纽约证券交易所代码:CRMD-GET评级)都是小盘股医疗公司,但哪一家更好?我们将根据两家公司的收益、估值、机构所有权、风险、盈利能力、股息和分析师建议的强项对其进行比较。
Institutional & Insider Ownership
机构与内部人持股
89.7% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 33.8% of CorMedix shares are held by institutional investors. 6.2% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ORIC制药89.7%的股份由机构投资者持有。相比之下,机构投资者持有CorMedex 33.8%的股份。ORIC制药6.2%的股份由公司内部人士持有。相比之下,CorMedex 2.8%的股份由公司内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司的长期表现将好于大盘。
Profitability
盈利能力
This table compares ORIC Pharmaceuticals and CorMedix's net margins, return on equity and return on assets.
该表比较了ORIC制药公司和CorMedex公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
ORIC Pharmaceuticals | N/A | -32.11% | -29.50% |
CorMedix | -25,202.44% | -48.87% | -44.76% |
净利润率 | 股本回报率 | 资产回报率 | |
奥瑞克制药公司 | 不适用 | -32.11% | -29.50% |
CorMedex | -25,202.44% | -48.87% | -44.76% |
Volatility and Risk
波动性和风险
Analyst Ratings
分析师评级
This is a breakdown of current ratings for ORIC Pharmaceuticals and CorMedix, as provided by MarketBeat.com.
这是由MarketBeat.com提供的ORIC制药公司和CorMedex的当前评级细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ORIC Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
CorMedix | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
奥瑞克制药公司 | 0 | 3 | 2 | 0 | 2.40 |
CorMedex | 0 | 0 | 0 | 0 | 不适用 |
ORIC Pharmaceuticals currently has a consensus price target of $22.00, suggesting a potential upside of 379.30%. Given ORIC Pharmaceuticals' higher probable upside, equities analysts clearly believe ORIC Pharmaceuticals is more favorable than CorMedix.
Oric PharmPharmticals目前的共识目标价为2200美元,暗示潜在上涨379.30%。鉴于ORIC制药公司更有可能上行,股票分析师显然认为ORIC制药公司比CorMedex更有利。
Earnings and Valuation
收益和估值
This table compares ORIC Pharmaceuticals and CorMedix's gross revenue, earnings per share and valuation.
该表格比较了ORIC制药公司和CorMedex公司的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ORIC Pharmaceuticals | N/A | N/A | -$78.71 million | ($2.15) | -2.13 |
CorMedix | $190,000.00 | 926.08 | -$28.21 million | ($0.79) | -5.42 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
奥瑞克制药公司 | 不适用 | 不适用 | -7,871万元 | ($2.15) | -2.13 |
CorMedex | $190,000.00 | 926.08 | -2,821万元 | ($0.79) | -5.42 |
CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CorMedex的收入和收益高于ORIC制药公司。CorMedex的市盈率低于ORIC PharmPharmticals,表明它目前是两只股票中更负担得起的一只。
Summary
摘要
ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.
在比较两只股票的12个因素中,Oric PharmPharmticals有8个超过CorMedex。
About ORIC Pharmaceuticals
ORIC制药公司简介
(Get Rating)
(获取评级)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
奥瑞克制药公司是一家临床阶段的生物制药公司,在美国发现和开发治疗癌症的疗法。其临床阶段的候选产品包括正在开发的CD73口服生物可用小分子抑制剂ORIC-533,用于耐受化疗和免疫治疗的治疗方案;ORIC-944,用于前列腺癌的多梳抑制复合体2的变构抑制剂;以及ORIC-114,一种脑穿透性口服生物可用不可逆抑制剂,旨在选择性地靶向表皮生长因子受体和人表皮生长因子受体2,对外显子20插入突变具有高效力。该公司还在开发针对其他癌症耐药机制的多个发现阶段的精确药物。它与Voronoi Inc.签订了许可和合作协议;与Mirati Treateutics,Inc.签订了许可协议。该公司成立于2014年,总部位于加利福尼亚州旧金山南部。
About CorMedix
关于CorMedex
(Get Rating)
(获取评级)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedex公司是一家生物制药公司,专注于在美国和国际上开发和商业化用于预防和治疗传染病和炎症性疾病的治疗产品。它的主要候选产品是DefenCath/Neutrolin,这是一种新型的抗感染解决方案,用于减少和预防临床环境中需要中心静脉导管的患者的导管相关感染和血栓形成,如血液透析、完全肠外营养和肿瘤学。该公司前身为Picton Holding Company,Inc.,于2007年1月更名为CorMedex,Inc.。CorMedex Inc.成立于2006年,总部设在新泽西州的伯克利高地。
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《ORIC制药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ORIC制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧